Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -17.28% and Operating profit at -56.68% over the last 5 years
2
The company has declared Negative results for the last 4 consecutive quarters
3
With ROE of 3.08%, it has a very attractive valuation with a 0.39 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,845 Million (Large Cap)
56.00
NA
3.81%
-0.42
0.90%
0.50
Revenue and Profits:
Net Sales:
746 Million
(Quarterly Results - Sep 2025)
Net Profit:
112 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.31%
0%
-18.31%
6 Months
2.58%
0%
2.58%
1 Year
8.67%
0%
8.67%
2 Years
-23.12%
0%
-23.12%
3 Years
-44.03%
0%
-44.03%
4 Years
-55.23%
0%
-55.23%
5 Years
0%
0%
0.0%
Hualan Biological Vaccine, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-22.59%
EBIT Growth (5y)
-147.19%
EBIT to Interest (avg)
70.38
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.31
Sales to Capital Employed (avg)
0.25
Tax Ratio
3.33%
Dividend Payout Ratio
58.21%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.43%
ROE (avg)
9.48%
Valuation key factors
Factor
Value
P/E Ratio
56
Industry P/E
Price to Book Value
1.73
EV to EBIT
80.40
EV to EBITDA
30.99
EV to Capital Employed
2.50
EV to Sales
6.28
PEG Ratio
NA
Dividend Yield
0.27%
ROCE (Latest)
3.12%
ROE (Latest)
3.08%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
746.00
34.30
2,074.93%
Operating Profit (PBDIT) excl Other Income
103.70
-15.20
782.24%
Interest
0.00
1.20
-100.00%
Exceptional Items
4.80
4.80
Consolidate Net Profit
111.50
-12.00
1,029.17%
Operating Profit Margin (Excl OI)
138.90%
-1,470.90%
160.98%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 2,074.93% vs 50.44% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 1,029.17% vs -136.59% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,123.10
2,401.50
-53.23%
Operating Profit (PBDIT) excl Other Income
236.70
1,026.80
-76.95%
Interest
6.20
6.20
Exceptional Items
24.30
39.70
-38.79%
Consolidate Net Profit
205.50
860.00
-76.10%
Operating Profit Margin (Excl OI)
84.30%
367.20%
-28.29%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -53.23% vs 32.02% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -76.10% vs 65.51% in Dec 2023
About Hualan Biological Vaccine, Inc. 
Hualan Biological Vaccine, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






